UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~ November 1714, 2012

Angiotech Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

British Columbia		000-30334		98-0226269
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1618 Station Street, Vancouver, BC, Canada V6A 1B6

(Address of principal executive offices)

(604) 221-7676 (Registrant’s Telephone Number, including area code)

(Registrant’s Telephone Number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 25.0402. ~~Triggering~~Departure ~~Events~~of ~~That~~Directors ~~Accelerate~~ or ~~Increase~~Certain aOfficers; ~~Direct~~Election ~~Financial~~of ~~Obligation~~Directors; orAppointment anof ~~Obligation~~Certain ~~under~~Officers; anCompensatory ~~Off-Balance~~Arrangements ~~Sheet~~of ~~Arrangement.~~Certain Officers

~~On September 17, 2012, Deutsche Bank National Trust Company~~ (~~the “Trustee”~~e), as trustee under the Indentures (as defined below), issued the notices of redemption filed herewith as Exhibits 99.1 and 99.2 and incorporated herein by this reference, on behalf of Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of British Columbia (the “Company”), to the record holder of the Company’s Senior Secured Floating Rate Notes due 2013 (the “FR Notes”, CUSIP Number 034918AH5) and the record holder of the Company’s Senior Floating Rate Notes due 2013 (the “Old FR Notes” and together with the FR Notes, the “Notes,” CUSIP Number 034918AF9). Pursuant to the Notice of Optional Partial Redemption, the Company has exercised its option to call for the partial redemption of $40,000,000 in aggregate principal amount of the FR Notes and pursuant to the Notice of Full Redemption, the Company has exercised its option to call for the full redemption of $22,000 in aggregate principal amount of the Old FR Notes at a redemption price of 100% of principal amount of the Notes, together with accrued and unpaid interest on the principal amount of the Notes to, but excluding, the redemption date, which is October 17, 2012. On the redemption date, the redemption price for the Notes will become due and payable. As of the date of the Notice of Optional Partial Redemption, there were approximately $100 million in aggregate principal amount of FR Notes outstanding.

~~The~~On ~~Company issued the FR Notes under that certain Indenture dated as of May~~November 127, ~~2011~~2012, byAngiotech ~~and~~Pharmaceuticals, Inc. ~~among~~(“Angiotech”) ~~the~~reached ~~Company,~~a asmediated ~~issuer,~~settlement ~~certain~~in ~~subsidiaries~~principle ofon the ~~Company~~termination aspayments ~~guarantors~~to ~~referred~~be made to ~~therein~~Dr. William ~~and Deutsche~~L. ~~Bank~~Hunter, ~~National~~the ~~Trust~~former ~~Company,~~President asand ~~trustee,~~Chief asExecutive ~~supplemented~~Officer byof ~~that~~Angiotech. ~~certain~~Dr. Hunter’s ~~Supplemental~~employment ~~Indenture,~~ceased ~~dated~~with asAngiotech ofeffective ~~August~~October 1317, ~~2012,~~2011. ~~among~~Pursuant ~~the~~to ~~Company,~~ the ~~guarantors~~terms ~~referred~~of tothe ~~therein,~~Settlement ~~and~~Agreement ~~Deutsche~~dated ~~Bank~~November ~~National Trust Company~~14, as2012 ~~trustee~~ (the ~~indenture, as supplemented, referred to as the~~ “FRSettlement ~~Notes Indenture~~Agreement”), Dr. Hunter ~~The~~received ~~Company~~a ~~issued~~cash ~~the~~settlement ~~Old~~of FR$6.5 ~~Notes~~million, ~~under~~inclusive ~~that certain Indenture dated as~~ of ~~December 11,~~legal ~~2006~~costs, ~~by and among~~ (the ~~Company,~~“Settlement asAmount”) ~~issuer,~~for ~~certain subsidiaries of~~ the ~~Company~~full ~~as guarantors referred to therein~~ and ~~Deutsche~~final ~~Bank~~settlement ~~National~~of ~~Trust~~all ~~Company,~~claims. asWithout ~~successor~~further ~~to Wells Fargo Bank~~consideration, NDr.~~A.,~~ Hunter assurrendered ~~trustee,~~all asequity ~~supplemented~~awards bygranted ~~that~~to ~~certain~~him ~~Supplemental~~under ~~Indenture,~~Angiotech’s ~~dated~~stock asincentive ofplan ~~May 12,~~and ~~2011,~~all ~~among~~such ~~the~~awards ~~Company,~~area ~~the guarantors~~and ~~referred~~will tobe ~~therein,~~deemed ~~and~~to ~~Deutsche~~be ~~Bank~~forfeited, ~~National~~terminated ~~Trust~~and ~~Company,~~cancelled asand ~~trustee~~of ~~(the~~no ~~indenture,~~further asforce ~~supplemented,~~and ~~referred~~effect. toDr. Hunter asand ~~the~~Angiotech ~~“Old~~each FRexecuted ~~Notes~~a ~~Indenture”~~mutual ~~and~~release ~~together~~in connection with ~~the~~entering FRinto ~~Notes Indenture,~~ the ~~“Indentures”)~~Settlement Agreement. ~~The redemption~~This ~~will~~Settlement beAmount ~~made~~had ~~pursuant~~been tofully ~~the~~accrued ~~terms~~for ofas ~~the~~at ~~Indentures.~~September 30, 2012.

~~Item 8.01. Other Events.~~2

On September 18, 2012, Angiotech issued a press release announcing the redemption of the Notes. A copy of Angiotech’s press release is furnished as Exhibit 99.3 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed herewith:

Exhibit		Description
99.1		Notice of Optional Partial Redemption dated September 17, 2012.
99.2		Notice of Full Redemption dated September 17, 2012.
99.3		Press Release, dated September 18, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ANGIOTECH PHARMACEUTICALS, INC. (Registrant)
	ANGIOTECH PHARMACEUTICALS, INC.
Date: September 20, 2012			By:	/s/ K. Thomas Bailey
	(Registrant)
				K. Thomas Bailey
Date: November 14, 2012	By:	/s/ K. Thomas Bailey
				Chief Executive Officer
		K. Thomas Bailey
		Chief Executive Officer

~~EXHIBIT INDEX~~ 3

Exhibit		Description
99.1		Notice of Optional Partial Redemption dated September 17, 2012.
99.2		Notice of Full Redemption dated September 17, 2012.
99.3		Press Release, dated September 18, 2012.

Filing Compare · ANGIOTECH PHARMACEUTICALS INC